MedTrace Logo

Oral LAT8881 in Neuropathic Pain

NCT03865953 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2021-06-14

Study results available
· View outcomes & findings →

Summary

This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.

Conditions

  • Neuropathic Pain
  • Diabetic Peripheral Neuropathy (DPN)
  • Post Herpetic Neuralgia (PHN)

Interventions

DRUG

LAT8881

LAT8881 oral capsule

DRUG

Placebo

Placebo oral capsule

Sponsors & Collaborators

  • Lateral Pharma Pty Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-09
Primary Completion
2020-04-19
Completion
2020-05-03
FDA Drug
Yes

Countries

  • Australia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03865953 on ClinicalTrials.gov